Assessment of the antigenic response in humans to a recombinant mutant interferon beta.
Cancer patients were given a recombinant mutant interferon beta by alternating IM and IV injections with weekly escalation of doses from 0.1 to 400 million U. Antibodies specific to the interferon of the IgG class were detected in 24 of 30 patients using an indirect enzyme-linked immunosorbent assay. Serum from only 1 of the 30 patients had detectable ability to neutralize interferon biological activity. The in vivo interferon serum level, assayed as antiviral activity immediately after IV injection, was not lower than levels seen in the absence of antibodies. Antibodies did not alter the kinetics of clearance of interferon from the serum after IV administration. Antibody levels progressively decreased when interferon administration was discontinued. In most patients antibody levels decreased during a maintenance period when interferon was being administered only by the IV route. In a subsequent trial interferon was given IV, and antibody developed in only 2 of 36 patients. In contrast, in a trial in which interferon was given IM, 20 of 25 patients developed antibody. No antibody-related clinical sequelae could be detected in any of these patients.
Konrad
M W
MW
Cetus Corporation, Emeryville, California 94608.
Childs
A L
AL
Merigan
T C
TC
Borden
E C
EC
D000917:Antibody Formation; D002986:Clinical Trials as Topic; D003001:Cloning, Molecular; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis*; D007370:Interferon Type I / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D009154:Mutation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use*
D007074:Immunoglobulin G; D007370:Interferon Type I; D011994:Recombinant Proteins